中泰证券研报指出，眼科基因疗法登上国际舞台，安全性略优于主要竞品。康弘药业作为国内眼科龙头，近期围绕眼底病变布局了多款新一代产品，包括基因疗法（KH631、KH658等）、高浓度康柏西普，均是沿着长效化方向进行开发，法瑞希单抗凭借给药间隔拉长到3-4个月的优势，2022年在美国获批上市后迅速放量，2024年全球销售额达到38.64亿瑞士法郎（约合44.00亿美元），同比增长68%，表明了长效化眼底病变用药的商业价值。考虑到公司主业稳健，创新药研发管线同时布局基因疗法、双毒素ADC、小分子平台，近期在数据读出方面进入兑现期，显现创新转型成效，维持“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.